STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[SCHEDULE 13G] Oruka Therapeutics, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G
Rhea-AI Filing Summary

Oruka Therapeutics, Inc. received a Schedule 13G reporting that a group of Viking-related entities and three named individuals may be deemed to beneficially own 2,666,690 shares of the company’s common stock, representing 5.5% of the outstanding class based on 48,384,150 shares outstanding following a private placement. The filing breaks ownership down: Viking Global Opportunities (VGOP) directly owns 1,600,014 shares (3.3%) and Viking Global Opportunities Drawdown (VGOD) directly owns 1,066,676 shares (2.2%). All reporting persons report only shared voting and dispositive power and no sole voting or dispositive power. The filing lists Oruka’s principal executive office in Menlo Park, CA, and provides the reporting persons’ business address in Stamford, CT. Signatures are dated 09/24/2025.

Positive
  • Disclosure compliance: The reporting group filed a Schedule 13G clearly disclosing beneficial ownership above the 5% threshold.
  • Detailed attribution: The filing provides a clear breakdown of ownership by entity (VGOP 1,600,014; VGOD 1,066,676) and percent of class.
Negative
  • None.

Insights

TL;DR: Viking-affiliated group holds a disclosed 5.5% stake, split between two investment vehicles (3.3% and 2.2%).

The Schedule 13G indicates passive reporting under Section 13(g) structure with shared voting and dispositive power across affiliated entities and three executive committee members. The stake equals 5.5% of shares outstanding after a recent private placement, which crosses the common 5% reporting threshold and therefore requires disclosure. The structure shows layered ownership through funds and GPs, but the filing reports no sole control and includes the required joint filing agreement. This is a disclosure of ownership rather than an assertion of control or a change in corporate governance.

TL;DR: Ownership is material for disclosure but presented as passive with shared authority, not an active control claim.

The filing clarifies beneficial ownership attribution under Rule 13d-3 through fund and GP relationships and notes that executive committee members may be deemed to beneficially own the shares held by the funds. All reported powers are shared; no individual or entity claims sole voting or dispositive authority. The document includes authorized signatures and a joint filing agreement, satisfying procedural requirements for a grouped 13G filing.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G




Comment for Type of Reporting Person: See Item 4


SCHEDULE 13G




Comment for Type of Reporting Person: See Item 4


SCHEDULE 13G




Comment for Type of Reporting Person: See Item 4


SCHEDULE 13G




Comment for Type of Reporting Person: See Item 4


SCHEDULE 13G




Comment for Type of Reporting Person: See Item 4


SCHEDULE 13G




Comment for Type of Reporting Person: See Item 4


SCHEDULE 13G




Comment for Type of Reporting Person: See Item 4


SCHEDULE 13G




Comment for Type of Reporting Person: See Item 4


SCHEDULE 13G




Comment for Type of Reporting Person: See Item 4


SCHEDULE 13G




Comment for Type of Reporting Person: See Item 4


SCHEDULE 13G




Comment for Type of Reporting Person: See Item 4


SCHEDULE 13G



VIKING GLOBAL INVESTORS LP
Signature:/s/ Scott M. Hendler
Name/Title:Scott M. Hendler on behalf of VIKING GLOBAL INVESTORS LP (1)(2)(3)
Date:09/24/2025
Viking Global Opportunities Parent GP LLC
Signature:/s/ Scott M. Hendler
Name/Title:Scott M. Hendler on behalf of Viking Global Opportunities Parent GP LLC (1)(2)(3)
Date:09/24/2025
Viking Global Opportunities GP LLC
Signature:/s/ Scott M. Hendler
Name/Title:Scott M. Hendler on behalf of Viking Global Opportunities GP LLC (1)(2)(3)
Date:09/24/2025
Viking Global Opportunities Portfolio GP LLC
Signature:/s/ Scott M. Hendler
Name/Title:Scott M. Hendler on behalf of Viking Global Opportunities Portfolio GP LLC (1)(2)(3)
Date:09/24/2025
Viking Global Opportunities Illiquid Investments Sub-Master LP
Signature:/s/ Scott M. Hendler
Name/Title:Scott M. Hendler on behalf of Viking Global Opportunities Illiquid Investments Sub-Master LP (1)(2)(3)
Date:09/24/2025
Viking Global Opportunities Drawdown GP LLC
Signature:/s/ Scott M. Hendler
Name/Title:Scott M. Hendler on behalf of Viking Global Opportunities Drawdown GP LLC (1)(2)(3)
Date:09/24/2025
Viking Global Opportunities Drawdown Portfolio GP LLC
Signature:/s/ Scott M. Hendler
Name/Title:Scott M. Hendler on behalf of Viking Global Opportunities Drawdown Portfolio GP LLC (1)(2)(3)
Date:09/24/2025
Viking Global Opportunities Drawdown (Aggregator) LP
Signature:/s/ Scott M. Hendler
Name/Title:Scott M. Hendler on behalf of Viking Global Opportunities Drawdown (Aggregator) LP (1)(2)(3)
Date:09/24/2025
HALVORSEN OLE ANDREAS
Signature:/s/ Scott M. Hendler
Name/Title:Scott M. Hendler on behalf of O. Andreas Halvorsen (1)
Date:09/24/2025
Ott David C.
Signature:/s/ Scott M. Hendler
Name/Title:Scott M. Hendler on behalf of David C. Ott (2)
Date:09/24/2025
Shabet Rose Sharon
Signature:/s/ Scott M. Hendler
Name/Title:Scott M. Hendler on behalf of Rose S. Shabet (3)
Date:09/24/2025

Comments accompanying signature: (1) Scott M. Hendler is signing on behalf of O. Andreas Halvorsen, individually and as an Executive Committee Member of VIKING GLOBAL PARTNERS LLC, on behalf of VIKING GLOBAL INVESTORS LP, and as an Executive Committee Member of VIKING GLOBAL OPPORTUNITIES PARENT GP LLC, on behalf of itself and VIKING GLOBAL OPPORTUNITIES GP LLC, VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC, VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP, VIKING GLOBAL OPPORTUNITIES DRAWDOWN GP LLC, VIKING GLOBAL OPPORTUNITIES DRAWDOWN PORTFOLIO GP LLC and VIKING GLOBAL OPPORTUNITIES DRAWDOWN (AGGREGATOR) LP, pursuant to an authorization and designation letter dated February 9, 2021, which was previously filed with the Commission as an exhibit to a Form 13G filed by Mr. Halvorsen on February 12, 2021 (SEC File No. 005-49737). (2) Scott M. Hendler is signing on behalf of David C. Ott, individually and as an Executive Committee Member of VIKING GLOBAL PARTNERS LLC, on behalf of VIKING GLOBAL INVESTORS LP, and as an Executive Committee Member of VIKING GLOBAL OPPORTUNITIES PARENT GP LLC, on behalf of itself and VIKING GLOBAL OPPORTUNITIES GP LLC, VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC, VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP, VIKING GLOBAL OPPORTUNITIES DRAWDOWN GP LLC, VIKING GLOBAL OPPORTUNITIES DRAWDOWN PORTFOLIO GP LLC and VIKING GLOBAL OPPORTUNITIES DRAWDOWN (AGGREGATOR) LP, pursuant to an authorization and designation letter dated February 9, 2021, which was previously filed with the Commission as an exhibit to a Form 13G filed by Mr. Halvorsen on February 12, 2021 (SEC File No. 005-49737). (3) Scott M. Hendler is signing on behalf of Rose S. Shabet, individually and as an Executive Committee Member of VIKING GLOBAL PARTNERS LLC, on behalf of VIKING GLOBAL INVESTORS LP, and as an Executive Committee Member of VIKING GLOBAL OPPORTUNITIES PARENT GP LLC, on behalf of itself and VIKING GLOBAL OPPORTUNITIES GP LLC, VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC, VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP, VIKING GLOBAL OPPORTUNITIES DRAWDOWN GP LLC, VIKING GLOBAL OPPORTUNITIES DRAWDOWN PORTFOLIO GP LLC and VIKING GLOBAL OPPORTUNITIES DRAWDOWN (AGGREGATOR) LP, pursuant to an authorization and designation letter dated February 9, 2021, which was previously filed with the Commission as an exhibit to a Form 13G filed by Mr. Halvorsen on February 12, 2021 (SEC File No. 005-49737).
Exhibit Information

EXHIBIT A - JOINT FILING AGREEMENT

FAQ

What stake does Viking Global Investors report in Oruka Therapeutics (ORKA)?

The reporting group may be deemed to beneficially own 2,666,690 shares, representing 5.5% of the class based on 48,384,150 shares outstanding.

How is the 5.5% ownership split among Viking-related entities?

Viking Global Opportunities (VGOP) directly owns 1,600,014 shares (3.3%) and Viking Global Opportunities Drawdown (VGOD) directly owns 1,066,676 shares (2.2%).

Do any reporting persons claim sole voting or dispositive power over the ORKA shares?

No. The filing reports 0 sole voting power and 0 sole dispositive power for all reporting persons and lists only shared voting and dispositive power.

When was this Schedule 13G filed and what event date does it reference?

Signatures on the filing are dated 09/24/2025 and the filing references an event date of 09/17/2025 related to the disclosure.

Where are Oruka Therapeutics’ and the reporting persons’ principal offices listed?

Oruka’s principal executive office is listed as 855 Oak Grove Avenue, Suite 100, Menlo Park, CA. The reporting persons’ business address is 600 Washington Boulevard, Floor 11, Stamford, CT.
Oruka Therapeutics Inc

NASDAQ:ORKA

ORKA Rankings

ORKA Latest News

ORKA Latest SEC Filings

ORKA Stock Data

1.37B
46.37M
3.82%
93.23%
8.54%
Biotechnology
Pharmaceutical Preparations
Link
United States
MENLO PARK